Background The steroid hormone, progesterone, inhibits contractions of the pregnant uterus
at all gestations. Antiprogestins (including mifepristone) have been developed to antagonise …

Since the original description of the structure of the antiprogestin, mifepristone, was
published, numerous related compounds have been synthesized which may function as …

OBJECTIVE: To assess the outcome of a regimen of a reduced dose of mifepristone
followed by one or two doses of vaginal misoprostol as a non-surgical method for …

Medical abortion regimens have become widely used, but the frequency of infection after
medical abortion is not well documented. This systematic review provides data on infectious …

Objectives To compare the efficacy of oral and vaginal administration of misoprostol after a
single oral dose of 200 mg of mifepristone and to investigate whether the efficacy can be …

OBJECTIVE: To estimate the immediate adverse events and safety of medical compared
with surgical abortion using high-quality registry data. METHODS: All women in Finland …

The frequencies of preeclampsia, fetal growth restriction, fetal demise, and low birthweight
are lower in subsequent pregnancies. Enhanced maternal cardiovascular adaptation …

The levonorgestrel intrauterine system (LNG-IUS) has been used internationally for over 15
years by 7 million women. Concern about providing the LNG-IUS to nulliparous women still …

In the first 18 months since mifepristone was approved by the Food and Drug Administration
(FDA) for use with misoprostol for early medical abortion, approximately 80,000 women …

Objective To assess women's acceptability, the efficacy and side effects of sublingual versus
vaginal administration of misoprostol in combination with mifepristone for medical abortion …